ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 06 2025

0mins

ORIC+4.62%

Should l Buy ORIC?

Source: Globenewswire

Clinical Trial Results: ORIC Pharmaceuticals presented data from the Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress, revealing a 67% objective response rate (ORR) in first-line patients, indicating the drug's potential in treating NSCLC with EGFR exon 20 mutations.
Safety Analysis: Enozerinib demonstrated favorable tolerability with mostly Grade 1 or 2 adverse events, and only three patients discontinued treatment due to adverse reactions, suggesting a safety profile that outperforms competitor therapies.
Performance in Brain Metastases: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), showcasing its exceptional efficacy in patients with brain metastases and reinforcing its competitive edge in the market.
Future Development Plans: ORIC plans to update data in mid-2026 and may initiate a Phase 3 trial, reflecting the company's confidence in enozertinib and its strategic positioning in the oncology sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.

ORIC

$10.42+Infinity%1D

Analyst Views on ORIC

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 19.60 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Analyst Rating

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 9.960

Low

15.00

Averages

19.60

High

25.00

Current: 9.960

Low

15.00

Averages

19.60

High

25.00

Piper Sandler

Kelsey Goodwin

Overweight

initiated

$22

2026-01-07

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$22

AI Analysis

2026-01-07

initiated

Overweight

Reason

Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals with an Overweight rating and $22 price target. The company's ORIC-944 is a potential best-in-class PRC2 inhibitor capable of becoming a standard of care treatment class in prostate cancer, the analyst tells investors in a research note. Piper believes the ORIC-944 clinical update in Q1 "is likely to represent a value creation event."

Wells Fargo

Overweight

upgrade

$19 -> $25

2025-12-08

Reason

Wells Fargo

Price Target

$19 -> $25

2025-12-08

upgrade

Overweight

Reason

Wells Fargo raised the firm's price target on Oric Pharmaceuticals to $25 from $19 and keeps an Overweight rating on the shares. While enozertinib has largely taken a back seat to ORIC-944, its data presented at ESMO Asia is intriguing and Wells thinks enough for investors to start assigning more credit. The firm believes shares should trade up.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ORIC

Unlock Now

About ORIC

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments

Jan 14 2026Newsfilter

Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.

Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026

Jan 14 2026PRnewswire

Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.

ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference

Jan 06 2026Globenewswire

Conference Presentation: ORIC Pharmaceuticals CEO Jacob M. Chacko will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the latest advancements in their oncology drug development, which is expected to attract investor interest.
Live Webcast: The presentation will be available via live webcast on the investor section of the company’s website, with a replay accessible for 90 days post-event, ensuring that investors unable to attend live can still access critical information.
Product Candidates: ORIC's clinical-stage candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), targeting various genetically defined cancers, highlighting the company's potential in innovative drug development aimed at overcoming therapeutic resistance.
Company Background: ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving patient lives by overcoming resistance in cancer, with offices in South San Francisco and San Diego, indicating a strategic presence in California's biotech hub.

ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation

Dec 16 2025Yahoo Finance

Price Target Increase: Wells Fargo raised the price target for ORIC Pharmaceuticals from $19 to $25, maintaining an Overweight rating, indicating confidence in the company's potential for growth.
Financial Position: As of September 30, ORIC Pharmaceuticals reported approximately $413 million in cash and investments, which is expected to support its operations through 2028 and fund upcoming Phase 3 trials.
Clinical Development: The company is making significant progress towards initiating Phase 3 trials for its lead candidates, ORIC-944 and enozertinib, which are anticipated to yield important data in the near future.
Investment Considerations: While ORIC is seen as a promising investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk, highlighting a competitive investment landscape.